PLX 73086

Drug Profile

PLX 73086

Alternative Names: AC-708; PLX73086

Latest Information Update: 15 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Plexxikon
  • Class Antineoplastics
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Giant cell tumour of tendon sheath; Solid tumours

Most Recent Events

  • 01 Feb 2016 Phase-I clinical trials in Giant cell tumour of tendon sheath (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02673736)
  • 01 Feb 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) (NCT02673736)
  • 01 Jan 2016 Preclinical trials in Solid tumours in USA (PO) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top